2 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Adrienne G. Waks: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) Sacituzumab Govitecan, Trastuzumab, Trastuzumab and Hyaluronidase-oysk - Her 2 Positive Breast Cancer, Breast Cancer Female | Phase 2 | Active not recruiting | Adrienne G. Waks | 28 | 2023-11-20 | 2026-02-24 |
| VS-6766+Abema+Fulv in Met HR+/HER- BC VS-6766, Abemaciclib, Fulvestrant - Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Adrienne G. Waks | 63 | 2023-02-23 | 2026-04-30 |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Vinorelbine, Trastuzumab, Avelumab - Breast Cancer | Phase 2 | Active not recruiting | Adrienne G. Waks | 100 | 2018-06-21 | 2026-07-20 |
| A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Pembrolizumab, Nab-Paclitaxel, Biopsy - Breast Cancer | Phase 1 | Completed | Adrienne G. Waks | 32 | 2017-02-23 | 2026-01-29 |
Breast Neoplasms (4)
Trastuzumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Fulvestrant (1) · Vinorelbine (1) · abemaciclib (1) · avelumab (1) · pembrolizumab (1) · sacituzumab govitecan (1) · utomilumab (1)
United States (4)
Adrienne G Waks, MD (1) · Adrienne Gropper Waks, MD (1) · Adrienne Waks, MD (1) · Adrienne Waks, MD, PhD (1)